Controlled Trial of Dexamethasone in Neonatal Chronic Lung Disease: A 3-Year Follow-Up

¹ Department of Pediatrics, Wrexham Park Hospital, Wrexham, United Kingdom
² Perinatal Trials Service, National Perinatal Epidemiology Unit, Radcliffe Infirmary, Oxford, United Kingdom, Adrian Grant is now at Health Services Research Unit, Polwarth Building, Foresterhill, Aberdeen AB9 2ZD, United Kingdom

Objective. We compared the effects of a policy of neonatal steroid administration versus placebo for babies chronically dependent on supplemental oxygen in terms of long-term health and development, judged at 3 years of age.

Design. Double-blind randomized controlled trial.

Setting. Thirty-one centers in the United Kingdom, Ireland, Belgium, Germany, Canada, and the United States.

Patients. Babies who were chronically dependent on supplemental oxygen between 2 and 12 weeks of age were recruited to the trial between 1986 and 1989. Sixty-two children were known to have died, 23 before discharge from the hospital and 10 afterward in the active group, compared with 25 and 4, respectively, in the placebo group. Information was available for 209 of the 212 eligible for follow-up (99%).

Interventions. A 1-week course of active dexamethasone phosphate 0.6 mg/kg/d (dexamethasone base 0.5 mg/kg/d) or saline placebo was given intravenously (or orally, if no intravenous line). There was an option to give a second tapering 9-day course if relapse occurred after initial improvement.

Outcome Measures. Information about respiratory problems, growth, neurodevelopment and disability, infection, and health service use when the children were 3 years old was ascertained from questionnaires to general practitioners, health visitors, and parents (and occasionally pediatricians).

Results. About half the children in both groups had been admitted to the hospital for respiratory problems, with more in the active than the placebo group having at least five outpatient consultations for these problems over the 3 years. Overall, the children were below average in height, weight, and head circumference. About one fifth had cerebral palsy, 8% some visual loss, and 16% hearing loss; 18% needed or were anticipated to need special schooling. There were no clear differences between the randomized groups. These overall conclusions were not altered by any of the prespecified secondary analyses.

Conclusions. Despite early benefits, there were no clear effects at 3 years of age. As 40% of the placebo group eventually received open steroids, even a trial of this size has limited statistical power to detect a moderate effect of the policy. Regardless of random allocation, overall morbidity was high, confirming that babies with protracted dependence on supplemental oxygen are at high risk of childhood disability and poor health.

This article has been cited by other articles:

				T. T. Wilson, L. Waters, C. C. Patterson, C. G. McCusker, N. M. Rooney, N. Marlow, and H. L. Halliday Neurodevelopmental and Respiratory Follow-up Results at 7 Years for Children From the United Kingdom and Ireland Enrolled in a Randomized Trial of Early and Late Postnatal Corticosteroid Treatment, Systemic and Inhaled (the Open Study of Early Corticosteroid Treatment). Pediatrics, June 1, 2006; 117(6): 2196 - 2205. [Abstract] [Full Text] [PDF]

				R. A. K. Jones and on behalf of the Collaborative Dexamethasone Trial Randomized, Controlled Trial of Dexamethasone in Neonatal Chronic Lung Disease: 13- to 17-Year Follow-up Study: I. Neurologic, Psychological, and Educational Outcomes Pediatrics, August 1, 2005; 116(2): 370 - 378. [Abstract] [Full Text] [PDF]

				R. A. K. Jones and on behalf of the Collaborative Dexamethasone Trial Randomized, Controlled Trial of Dexamethasone in Neonatal Chronic Lung Disease: 13- to 17-Year Follow-up Study: II. Respiratory Status, Growth, and Blood Pressure Pediatrics, August 1, 2005; 116(2): 379 - 384. [Abstract] [Full Text] [PDF]

				L. W. Doyle, H. L. Halliday, R. A. Ehrenkranz, P. G. Davis, and J. C. Sinclair Impact of Postnatal Systemic Corticosteroids on Mortality and Cerebral Palsy in Preterm Infants: Effect Modification by Risk for Chronic Lung Disease Pediatrics, March 1, 2005; 115(3): 655 - 661. [Abstract] [Full Text] [PDF]

				T. F. Yeh, Y. J. Lin, H. C. Lin, C. C. Huang, W. S. Hsieh, C. H. Lin, and C. H. Tsai Outcomes at School Age after Postnatal Dexamethasone Therapy for Lung Disease of Prematurity N. Engl. J. Med., March 25, 2004; 350(13): 1304 - 1313. [Abstract] [Full Text] [PDF]

				G. Wang, X. Guo, and J. Floros Human SP-A 3'-UTR variants mediate differential gene expression in basal levels and in response to dexamethasone Am J Physiol Lung Cell Mol Physiol, May 1, 2003; 284(5): L738 - L748. [Abstract] [Full Text] [PDF]

				C Romagnoli, E Zecca, R Luciano, G Torrioli, and G Tortorolo A three year follow up of preterm infants after moderately early treatment with dexamethasone Arch. Dis. Child. Fetal Neonatal Ed., July 1, 2002; 87(1): F55 - 58. [Abstract] [Full Text] [PDF]

				B. A. Banks Postnatal Dexamethasone for Bronchopulmonary Dysplasia: A Systematic Review and Meta-analysis of 20 Years of Clinical Trials NeoReviews, February 1, 2002; 3(2): e24 - 34. [Full Text]

				K. J. Barrington Hazards of systemic steroids for ventilator-dependent preterm infants: What would a parent want? Can. Med. Assoc. J., July 1, 2001; 165(1): 33 - 34. [Full Text] [PDF]

				E S Shinwell, M Karplus, D Reich, Z Weintraub, S Blazer, D Bader, S Yurman, T Dolfin, A Kogan, S Dollberg, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2000; 83(3): 177F - 181. [Abstract] [Full Text]

				C G D Brook;, I. HUGHES;, and C. J H KELNAR Antenatal treatment of a mother bearing a fetus with congenital adrenal hyperplasia Arch. Dis. Child. Fetal Neonatal Ed., May 1, 2000; 82(3): 176F - 181. [Full Text]

				B. J. Stoll, M. Temprosa, J. E. Tyson, L.-A. Papile, L. L. Wright, C. R. Bauer, E. F. Donovan, S. B. Korones, J. A. Lemons, A. A. Fanaroff, et al. Dexamethasone Therapy Increases Infection in Very Low Birth Weight Infants Pediatrics, November 1, 1999; 104(5): 63e - 63. [Abstract] [Full Text]

				T. M. O'Shea, J. M. Kothadia, K. L. Klinepeter, D. J. Goldstein, B. G. Jackson, and R. G. Weaver Randomized Placebo-controlled Trial of a 42-Day Tapering Course of Dexamethasone to Reduce the Duration of Ventilator Dependency in Very Low Birth Weight Infants: Outcome of Study Participants at 1-Year Adjusted Age Pediatrics, July 1, 1999; 104(1): 15 - 21. [Abstract] [Full Text]

				T F Fok, K Lam, M Dolovich, P C Ng, W Wong, K L Cheung, and K W So Randomised controlled study of early use of inhaled corticosteroid in preterm infants with respiratory distress syndrome Arch. Dis. Child. Fetal Neonatal Ed., May 1, 1999; 80(3): 203F - 208. [Abstract] [Full Text]

				T. F. Yeh, Y. J. Lin, C. C. Huang, Y. J. Chen, C. H. Lin, H. C. Lin, W. S. Hsieh, and Y. J. Lien Early Dexamethasone Therapy in Preterm Infants: A Follow-up Study Pediatrics, May 1, 1998; 101 (5): e7 - e7. [Abstract] [Full Text] [PDF]

				L.-A. Papile, J. E. Tyson, B. J. Stoll, L. L. Wright, E. F. Donovan, C. R. Bauer, H. Krause-Steinrauf, J. Verter, S. B. Korones, J. A. Lemons, et al. A Multicenter Trial of Two Dexamethasone Regimens in Ventilator-Dependent Premature Infants N. Engl. J. Med., April 16, 1998; 338(16): 1112 - 1119. [Abstract] [Full Text] [PDF]

	Home | My Pediatrics | Journal Information | Current Issue | Past Issues | Subscriptions & Services | Contact Us Click here for faster international access © 1995 American Academy of Pediatrics. All rights reserved.